The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide up to $328m to Clover Biopharmaceuticals for the development of Covid-19 vaccine candidate.
Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m.
US-based PerkinElmer has agreed to acquire UK-based cell engineering company Horizon Discovery Group in a deal valued at around $383m.
Swiss pharmaceutical company Novartis has acquired gene therapy company Vedere Bio in a deal valued at around $280m.
Machine-learning driven drug discovery and development company insitro has entered into a five-year collaboration with Bristol Myers Squibb to develop treatments for neurodegenerative disorders.
Novartis and Molecular Partners announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.
German pharmaceutical and life sciences company Bayer has agreed to acquire US-based clinical-stage gene therapy company Asklepios BioPharmaceutical (AskBio) for up to $4bn.
Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its USD$105 million Series D financing.
EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.
Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.